Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia.
Schierl
Michael
M
Department of Dermatology and Venerology, Hospital Hietzing, Wolkersbergenstrasse 1, A-1130 Vienna, Austria. michael.schierl@gmx.at
Foedinger
Dagmar
D
Geissler
Klaus
K
Rappersberger
Klemens
K
Feldmann
Robert
R
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000150:complications* / Q000473:pathology; D010392:Pemphigus / Q000150:complications* / Q000188:drug therapy; D000069283:Rituximab; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine